Market Challenge: Mylan A Buy?

| About: Mylan Inc (MYL)

Summary

Mylan has been in the crosshairs of regulators and Congress for its pricing of the EpiPen for treating allergic reactions.

But after the company settled a case concerning Medicaid issues, is the stock now a buy?

Offer your perspective below!

Update: Most are bullish on Mylan's prospects.

  • Buy - The settlement and EpiPen's promise will deliver for shareholders - 60%
  • Hold - Mylan is more than just EpiPen - 24.5%
  • Sell - Negative headlines, more government scrutiny may impact the stock - 15.5%

Thanks to everyone who participated in today's poll. We're back tomorrow with more Market Challenge.

*****

Mylan (NASDAQ:MYL) has been in the crosshairs of regulators and Congress for its pricing of the EpiPen for treating allergic reactions.

But after the company settled a case concerning Medicaid issues, is the stock now a buy?

The stock had a strong climb last week. And shares are up today.

Your thoughts on Mylan? Is it a buy, hold or sell?

Offer your ideas below!

About this article:

Expand
Tagged: , Drugs - Generic, Market News Article
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here